Lord, Abbett & Co
MRTX

Lord, Abbett & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Lord, Abbett & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-287,946
Closed -$20.1M – 659
2022
Q3 		$20.1M Sell
287,946
-25,349
-8% -$1.88M 0.07% 329
2022
Q2 		$21M Buy
313,295
+5,010
+2% +$319K 0.07% 326
2022
Q1 		$25.3M Sell
308,285
-189,155
-38% -$19.3M 0.07% 342
2021
Q4 		$73M Buy
497,440
+23,349
+5% +$3.63M 0.17% 191
2021
Q3 		$83.9M Buy
474,091
+116,561
+33% +$18.8M 0.2% 160
2021
Q2 		$57.8M Sell
357,530
-262,793
-42% -$42.2M 0.14% 224
2021
Q1 		$106M Sell
620,323
-139,798
-18% -$27.7M 0.27% 107
2020
Q4 		$167M Buy
760,121
+364,634
+92% +$78.8M 0.44% 47
2020
Q3 		$65.7M Sell
395,487
-253,968
-39% -$34.8M 0.21% 141
2020
Q2 		$74.1M Sell
649,455
-20,810
-3% -$2.02M 0.26% 112
2020
Q1 		$51.5M Sell
670,265
-47,294
-7% -$4.24M 0.23% 130
2019
Q4 		$92.5M Buy
717,559
+331,376
+86% +$32M 0.31% 93
2019
Q3 		$30.1M Buy
386,183
+9,492
+3% +$891K 0.1% 325
2019
Q2 		$38.8M Sell
376,691
-253,693
-40% -$19.8M 0.13% 274
2019
Q1 		$46.2M Buy
630,384
+364,005
+137% +$24.8M 0.15% 218
2018
Q4 		$11.3M Buy
266,379
+6,486
+2% +$258K 0.04% 508
2018
Q3 		$12.2M Buy
+259,893
New +$14.5M 0.03% 589
2015
Q3 		– Sell
-162,506
Closed -$5.11M – 974
2015
Q2 		$5.11M Buy
+162,506
New +$4.79M 0.01% 765

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Lord, Abbett & Co's MRTX Position: Q4 2022 in Review

Lord, Abbett & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 287,946 shares — an estimated $20.1M sold.

Lord, Abbett & Co first reported a position in MRTX in Q2 2015 and held it in 18 quarters. The position peaked at $167M in Q4 2020. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Lord, Abbett & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 287,946 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $20.1M.
  • Lord, Abbett & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
  • Lord, Abbett & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $167M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Lord, Abbett & Co's 13F filing for Q4 2022, filed 10 Feb 2023.